Skip to main navigation
  • Skip to main content
  • Skip to footer
Scholar Rock

Scholar Rock - Utility Menu

  • Careers
  • Contact Us

Main navigation

  • Our Company
    • Management Team
    • Board of Directors
    • Partnering
    • Learn About Our Company
  • Our Science
    • Structural Insights & the Growth Factor Precursor
    • Platform
    • Publications & Posters
    • Learn About Our Science
  • Our Pipeline
    • Spinal Muscular Atrophy
    • Oncology
    • Fibrosis
    • Iron-Restricted Anemia
    • Clinical Trials
    • Learn About Our Pipeline
  • Patients & Families
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Committee Composition
      • Management Team
      • Board of Directors
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media

Breadcrumb

Home / Investors & Media

Investor overview

Explore Investors & Media

  • Investor Overview
  • Press Releases
    • Archived Press Releases
  • Events & Presentations
  • Corporate Governance
    • Committee Composition
    • Management Team
    • Board of Directors
  • Financials & Filings
    • SEC Filings
  • Stock Information
    • Historical Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Investor FAQs
  • Contact IR or Media

Corporate Profile

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced investigational product candidate, apitegromab (SRK-015), a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle, is in development for the treatment of spinal muscular atrophy, or SMA. Apitegromab was evaluated in our TOPAZ Phase 2 proof-of-concept trial in patients with later-onset (Type 2 and Type 3) SMA and we shared positive 12-month top-line data demonstrating apitegromab’s therapeutic potential in April 2021. We initiated our SAPPHIRE Phase 3 registrational trial in patients with later-onset Type 2 and Type 3 SMA in November 2021. In addition, we are conducting our DRAGON Phase 1 proof-of-concept trial for SRK-181, a selective inhibitor of latent TGFβ1 activation, in patients with locally advanced and metastatic solid tumors. We believe SRK-181 has the potential to overcome resistance and meaningfully increase the number of patients who may benefit from checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 therapies.

Utilizing our proprietary platform, we are creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and iron disorders.

News

View More Press Releases

July 1, 2022

Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)

Read This Press Release

June 17, 2022

Scholar Rock Announces $205 Million Registered Direct Offering

Read This Press Release

June 17, 2022

Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)

Read This Press Release

Events

View More Events

June 17, 2022 8:30 AM EDT

The 2022 Annual Cure SMA Conference

View This Event

June 9, 2022 8:00 AM EDT

Jefferies Global Healthcare Conference 2022

View This Event

March 7, 2022 9:10 AM EST

Cowen’s 42nd Annual Health Care Conference

View This Event

  • RSS Feeds
  • Search

Footer

SCHOLAR ROCK
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
info@scholarrock.com

Contact Us

LinkedIn Twitter

Scholar Rock - Main navigation

  • Our Company
    • Management Team
    • Board of Directors
    • Partnering
    • Learn About Our Company
  • Our Science
    • Structural Insights & the Growth Factor Precursor
    • Platform
    • Publications & Posters
    • Learn About Our Science
  • Our Pipeline
    • Spinal Muscular Atrophy
    • Oncology
    • Fibrosis
    • Iron-Restricted Anemia
    • Clinical Trials
    • Learn About Our Pipeline
  • Patients & Families
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Committee Composition
      • Management Team
      • Board of Directors
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Community Guidelines
  • Expanded Access Policy
  • Terms of Use
  • Privacy Policy

Scholar Rock, Inc. © 2022 All Rights Reserved

    Scholar Rock - Main navigation

  • Our Company
    • Management Team
    • Board of Directors
    • Partnering
    • Learn About Our Company
  • Our Science
    • Structural Insights & the Growth Factor Precursor
    • Platform
    • Publications & Posters
    • Learn About Our Science
  • Our Pipeline
    • Spinal Muscular Atrophy
    • Oncology
    • Fibrosis
    • Iron-Restricted Anemia
    • Clinical Trials
    • Learn About Our Pipeline
  • Patients & Families
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Committee Composition
      • Management Team
      • Board of Directors
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Scholar Rock - Utility Menu

  • Careers
  • Contact Us